On July 31, 2020 Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, reported that the divestment of its remaining shareholding in VISUfarma, a pan-European ophthalmic specialty pharmaceutical company, has closed as expected and, as per the press release of 10 July 2020, Nicox has received the funds of €5 million (Press release, NicOx, JUL 31, 2020, View Source;utm_medium=rss&utm_campaign=nicox-receives-e5-million-upon-closing-of-visufarma-divestment-2 [SID1234562618]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!